Co-Authors
This is a "connection" page, showing publications co-authored by LUIS E FAYAD and FULIANG CHU.
Connection Strength
0.056
-
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77.
Score: 0.029
-
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1613-23.
Score: 0.026